Hei-Cheul Jeung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7637246/publications.pdf

Version: 2024-02-01

42	707	623734	580821
papers	citations	14 h-index	25 g-index

44	44	44	1347
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, TPS624-TPS624.	1.6	0
2	Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis. Cancers, 2022, 14, 2038.	3.7	2
3	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2022, 40, 4001-4001.	1.6	5
4	Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers, 2021, 13, 1806.	3.7	7
5	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 689587.	2.8	11
6	Abstract 1295: SJP1901, a small molecule inhibitor targeting hippo pathway by directly inhibiting TEAD palmitoylation in hippo pathway-dependent cancer. , 2021, , .		0
7	Abstract CT159: Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC). , 2021, , .		2
8	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467	1.6	31
9	PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. Experimental Cell Research, 2021, 409, 112930.	2.6	4
10	Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients. Frontiers in Oncology, 2020, 10, 1581.	2.8	18
11	MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13529-13540.	7.1	33
12	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Oncology, 2020, 38, 3081-3081.	1.6	24
13	Early nutritional risk assessment by NRS 2002 to predict survival in patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2020, 38, 505-505.	1.6	2
14	HER2 Regulates Cancer Stem Cell Activities via the Wnt Signaling Pathway in Gastric Cancer Cells. Oncology, 2019, 97, 311-318.	1.9	14
15	Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer. Frontiers in Oncology, 2019, 9, 366.	2.8	19
16	The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy. Nutrients, 2019, 11, 1145.	4.1	59
17	Association between early nutritional risk and overall survival in patients with advanced pancreatic cancer: A single-center retrospective study. Clinical Nutrition ESPEN, 2019, 30, 94-99.	1.2	14
18	Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. Yonsei Medical Journal, 2019, 60, 604.	2.2	12

#	Article	IF	Citations
19	Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. Journal of Rheumatic Diseases, 2019, 26, 221.	1.1	3
20	Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study. Cancer Research and Treatment, 2019, 51, 1612-1619.	3.0	12
21	Fortyâ€nine gastric cancer cell lines with integrative genomic profiling for development of câ€MET inhibitor. International Journal of Cancer, 2018, 143, 151-159.	5.1	24
22	Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study. Journal of Thoracic Disease, 2018, 10, 2279-2287.	1.4	18
23	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer, 2018, 18, 1116.	2.6	51
24	Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy. Frontiers in Oncology, 2018, 8, 457.	2.8	81
25	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Biochemical Pharmacology, 2017, 123, 73-84.	4.4	3
26	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Biochemical Pharmacology, 2017, 138, 163-173.	4.4	9
27	ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. British Journal of Cancer, 2017, 117, 1798-1809.	6.4	35
28	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Oncology Letters, 2017, 14, 2385-2392.	1.8	6
29	Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Research and Treatment, 2017, 49, 1127-1139.	3.0	25
30	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2051-2059.	2.5	12
31	Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Research and Treatment, 2016, 48, 1253-1263.	3.0	15
32	The Effect of Disintegrinâ€“Metalloproteinase ADAM9 in Gastric Cancer Progression. Molecular Cancer Therapeutics, 2014, 13, 3074-3085.	4.1	35
33	Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. Journal of Psychosomatic Research, 2014, 77, 76-80.	2.6	15
34	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14652-e14652.	1.6	0
35	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 801-810.	1.4	14
36	A randomized phase 2 study of docetaxel and Sâ€1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer, 2011, 117, 2050-2057.	4.1	42

#	Article	IF	Citations
37	Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 29-35.	1.3	2
38	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. International Journal of Oncology, 2009, 34, 787-96.	3.3	1
39	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemotherapy and Pharmacology, 2009, 63, 919-927.	2.3	6
40	Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status.. Blood, 2009, 114, 2637-2637.	1.4	0
41	Multiâ€institutional Phase II Study of Sâ€1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. Oncologist, 2007, 12, 543-554.	3.7	33
42	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2006, 59, 313-320.	2.3	8